Market Overview:
The global human respiratory syncytial virus drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of respiratory syncytial virus (RSV) infections, rising demand for novel therapeutics, and growing awareness about RSV infections. The global human respiratory syncytial virus drugs market is segmented on the basis of type into approved drugs and off-label drugs. The approved drugs segment is further sub-segmented into monoclonal antibodies and small molecules. The monoclonal antibodies sub-segment is expected to grow at a higher CAGR during the forecast period as compared to other segments due to their high efficacy and safety profile. On the basis of application, the global human respiratory syncytial virus drugs market is segmented into clinical diagnostic, laboratories physicians' office, laboratories hospitals, and others. Clinical diagnostic accounted for majority share in 2017 owing to rising demand for accurate diagnosis of RSV infections across all regions. Geographically, the global human respiratory syncial virus drug market is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa (MEA).
Product Definition:
Human Respiratory Syncytial Virus Drugs is a type of drug used to treat human respiratory syncytial virus (HRSV), which is a common cause of severe respiratory illness in young children and can also occur in adults. These drugs may be administered as an aerosol or as an oral suspension.
Approved Drugs:
Approved drugs, it's usage.
The global Approved Drugs, It’s Usage and Growth Factor in the Human Respiratory Syncytial Virus (HRSV) Drugs market size was valued at USD 473.0 million in 2016.
Off-Label Drugs:
Off-label drug is a pharmaceutical product which has been approved by the Food and Drug Administration (FDA) for a particular use other than that for which it was prescribed. The FDA does not regulate off-label drugs; therefore, manufacturers are free to make claims about the benefits of their products. However, there are legal implications associated with making false or fraudulent statements in an advertisement regarding such products.
Application Insights:
The clinical diagnostic application segment dominated the global market in 2017. This is due to the high prevalence of diseases, such as asthma and bronchitis, caused by HRRSV. In addition, an increase in spending capacity of companies for research & development activities for new product launch is expected to boost revenue generation in this segment over the forecast period.
The laboratories physicians' office application accounted for a significant share owing to increasing demand from infectious disease specialists and pathologists working at hospitals & clinics. These professionals analyze viral samples collected from patients with similar symptoms or complaints regarding cough and fever who have recently traveled abroad or come back from abroad.
Regional Analysis:
North America dominated the global HRV drugs market in 2016. This can be attributed to the high prevalence of this disease, increasing R&D activities by various companies for developing novel therapies and better treatment methods, and rising healthcare expenditure in this region. The U.S., which is at the forefront of North America, accounted for a large share of revenue generation owing to its well-developed healthcare infrastructure along with high per capita health spending capacity. Moreover, it has one of the highest number of reported cases worldwide as well as death due to this coronavirus infection globally (CDC).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to an increase in government initiatives pertaining towards tackling respiratory diseases such as asthma and COPD coupled with growing awareness about these conditions among patients & general public alike.
Growth Factors:
- Increasing incidence of respiratory syncytial virus (RSV) infections across the globe.
- Growing awareness about the benefits of human respiratory syncytial virus drugs among patients and healthcare professionals.
- Rising demand for human respiratory syncytial virus drugs due to increasing number of immunocompromised patients globally.
- Technological advancements in human respiratory syncytial virus drug development and commercialization process that would offer better treatment outcomes for patients infected with RSV viruses . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Respiratory Syncytial Virus Drugs Market Research Report
By Type
Approved Drugs, Off-Label Drugs
By Application
Clinical Diagnostic, Laboratories Physicians' Office, Laboratories Hospitals
By Companies
AstraZeneca, AbbVie, GSK, Teva Pharmaceutical, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
131
Number of Tables & Figures
92
Customization Available
Yes, the report can be customized as per your need.
Global Human Respiratory Syncytial Virus Drugs Market Report Segments:
The global Human Respiratory Syncytial Virus Drugs market is segmented on the basis of:
Types
Approved Drugs, Off-Label Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinical Diagnostic, Laboratories Physicians' Office, Laboratories Hospitals
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- AbbVie
- GSK
- Teva Pharmaceutical
- AstraZeneca
Highlights of The Human Respiratory Syncytial Virus Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Approved Drugs
- Off-Label Drugs
- By Application:
- Clinical Diagnostic
- Laboratories Physicians' Office
- Laboratories Hospitals
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Respiratory Syncytial Virus Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human respiratory syncytial virus (HRSV) drugs are medications used to treat the symptoms of HRSV infection. These medications can help to relieve the symptoms of a cold or the flu, such as fever, cough, and congestion.
Some of the major companies in the human respiratory syncytial virus drugs market are AstraZeneca, AbbVie, GSK, Teva Pharmaceutical, AstraZeneca.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Respiratory Syncytial Virus Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Respiratory Syncytial Virus Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Respiratory Syncytial Virus Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Respiratory Syncytial Virus Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Respiratory Syncytial Virus Drugs Market Size & Forecast, 2018-2028
4.5.1 Human Respiratory Syncytial Virus Drugs Market Size and Y-o-Y Growth
4.5.2 Human Respiratory Syncytial Virus Drugs Market Absolute $ Opportunity
Chapter 5 Global Human Respiratory Syncytial Virus Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type
5.2.1 Approved Drugs
5.2.2 Off-Label Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Human Respiratory Syncytial Virus Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Human Respiratory Syncytial Virus Drugs Market Size Forecast by Applications
6.2.1 Clinical Diagnostic
6.2.2 Laboratories Physicians' Office
6.2.3 Laboratories Hospitals
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Respiratory Syncytial Virus Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Respiratory Syncytial Virus Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Human Respiratory Syncytial Virus Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type
9.6.1 Approved Drugs
9.6.2 Off-Label Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Human Respiratory Syncytial Virus Drugs Market Size Forecast by Applications
9.10.1 Clinical Diagnostic
9.10.2 Laboratories Physicians' Office
9.10.3 Laboratories Hospitals
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Human Respiratory Syncytial Virus Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type
10.6.1 Approved Drugs
10.6.2 Off-Label Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Human Respiratory Syncytial Virus Drugs Market Size Forecast by Applications
10.10.1 Clinical Diagnostic
10.10.2 Laboratories Physicians' Office
10.10.3 Laboratories Hospitals
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Human Respiratory Syncytial Virus Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type
11.6.1 Approved Drugs
11.6.2 Off-Label Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Size Forecast by Applications
11.10.1 Clinical Diagnostic
11.10.2 Laboratories Physicians' Office
11.10.3 Laboratories Hospitals
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Human Respiratory Syncytial Virus Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type
12.6.1 Approved Drugs
12.6.2 Off-Label Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Human Respiratory Syncytial Virus Drugs Market Size Forecast by Applications
12.10.1 Clinical Diagnostic
12.10.2 Laboratories Physicians' Office
12.10.3 Laboratories Hospitals
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Human Respiratory Syncytial Virus Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Human Respiratory Syncytial Virus Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Human Respiratory Syncytial Virus Drugs Market Size Forecast by Type
13.6.1 Approved Drugs
13.6.2 Off-Label Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Human Respiratory Syncytial Virus Drugs Market Size Forecast by Applications
13.10.1 Clinical Diagnostic
13.10.2 Laboratories Physicians' Office
13.10.3 Laboratories Hospitals
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Respiratory Syncytial Virus Drugs Market: Competitive Dashboard
14.2 Global Human Respiratory Syncytial Virus Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 AbbVie
14.3.3 GSK
14.3.4 Teva Pharmaceutical
14.3.5 AstraZeneca
